Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWPU | ISIN: US91381U2006 | Ticker-Symbol: 9U90
Tradegate
04.06.25 | 12:53
0,620 Euro
-2,52 % -0,016
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
UNITY BIOTECHNOLOGY INC Chart 1 Jahr
5-Tage-Chart
UNITY BIOTECHNOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5650,64211:18
0,5650,64211:13

Aktuelle News zur UNITY BIOTECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Unity Biotech stock rating downgraded at H.C. Wainwright2
16.05.Mizuho cuts Unity Biotech stock rating, slashes price target to $14
05.05.Unity Biotechnology, Inc. - 8-K, Current Report3
UNITY BIOTECHNOLOGY Aktie jetzt für 0€ handeln
01.05.Unity Biotechnology, Inc.: UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting4
23.04.H.C. Wainwright maintains $4 target on Unity Biotech stock3
22.04.Unity Biotechnology GAAP EPS of -$0.43 misses by $0.032
22.04.UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates152SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
► Artikel lesen
22.04.Unity Biotechnology, Inc. - 10-Q, Quarterly Report3
22.04.Unity Biotechnology, Inc. - 8-K, Current Report2
11.04.Unity Biotechnology, Inc. - 10-K/A, Annual Report1
25.03.H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating19
25.03.Mizuho maintains Unity Biotechnology Outperform rating3
24.03.Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls5
24.03.UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial10
24.03.Unity Biotechnology, Inc.: UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema215Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence...
► Artikel lesen
23.03.Unity Biotechnology, Inc.: UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 20253
17.03.Unity Biotechnology, Inc. - 8-K, Current Report3
10.03.Unity Biotechnology, Inc.: UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors203SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today...
► Artikel lesen
07.03.UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates329SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today...
► Artikel lesen
07.03.Unity Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1